Knowledgeable panel says new $56K Alzheimer’s drug is unproven—and value $8,400 max

https://ift.tt/eA8V8J
Enlarge / The outside of the headquarters of biotechnology firm Biogen in Cambridge, Massachusetts. Getty | Boston Globe Biogen’s new Alzheimer’s drug Aduhelm continues to face opposition after its contentious approval by the Meals and Drug Administration final month—which the FDA now says ought to be independently investigated. Some insurers say they will not pay …
Source: https://ift.tt/3xLxnLv